Georges K. Haddad

Infected femoral artery false aneurysms in drug addicts: evolution of selective vascular reconstruction.

Fifty-four infected femoral artery false aneurysms resulting from chronic drug addiction were managed surgically with an 11% amputation rate and no mortality. Angiography localized the arterial segment involved, which in turn influenced the type of operation performed. Twenty-six aneurysms of anatomically isolated femoral artery segments were ligated and excised without resultant amputation. However, of the 28 aneurysms involving the common femoral bifurcation, 18 required triple ligation and excision that led to six amputations. Six of the 28 aneurysms were reconstructed with autogenous saphenous vein grafts, three by prosthetic grafts, and one by primary anastomosis. No amputations followed vascular reconstruction. However, all synthetic grafts eventually developed septic complications that required graft removal. On the basis of this experience we recommend ligation and excision for single artery segment aneurysms and immediate autogenous reconstruction for selected common femoral bifurcation lesions. This approach has proved safe and has reduced our amputation and graft complication rates. Extensive uncontrollable wound sepsis may contraindicate revascularization. Under these circumstances we estimate a 33% risk of amputation when the common femoral bifurcation is excised.

Basilic Vein Transposition: What is the Optimal Technique?

OBJECTIVES To compare the outcome of the one-stage basilic vein transposition (BVT) fistula with a modified, two-stage technique. DESIGN Retrospective case-controlled study, performed in an academic centre. MATERIAL A total of 173 candidates for BVT fistula (87 males, mean age 61 years). METHODS In one-stage BVT, the basilic vein is mobilised through a single incision, placed inside an anterolateral arm tunnel and anastomosed with the brachial artery. In two-stage procedures, the fistula-arterial anastomosis is created first, followed by the second stage, after fistula maturation several weeks later, when the basilic vein is mobilised through two skip incisions, transected near the anastomosis, placed inside an anterolateral arm tunnel and reanastomosed. Morbidity and fistula maturation rate were the main outcome measures. RESULTS In one-stage BVT (n=76), the incidence of venous hypertension, wound haematomas and all complications (17%, 13% and 43%, respectively) was significantly higher than in two-stage procedures (n=98) (4%, p=0.004, 3%, p=0.012 and 11%, p<0.001, respectively). Time (68 days) to fistula use was significantly decreased in one-stage BVT than in two-stage procedures (132 days, p<0.001) but failure to mature rate was equivalent (15% vs. 18%, p=0.49). CONCLUSIONS Our results indicate that the two-stage BVT fistula through two skip-arm incisions is superior to the established one-stage procedure in terms of less morbidity but at the cost of a second operation and longer time to access use. Further research comparing these two techniques is necessary. Until this issue is resolved, an individualised approach is suggested.

Effectiveness of a New Tunneled Catheter in Preventing Catheter Malfunction: A Comparative Study

PURPOSE To compare infection and malfunction rates of two different types of antimicrobial-eluting tunneled cuffed catheters (TCCs) for hemodialysis. MATERIALS AND METHODS The HemoSplit TCC with BioBloc (silver sulfadiazine) coating (n = 100, control group) and the Tal Palindrome Ruby TCC, which has a novel silver antimicrobial sleeve and a spiral-z tip design (n = 100, study group), were compared in this case-controlled study. The main endpoints were TCC infection and malfunction. RESULTS Primary-assisted TCC patency was significantly reduced with the BioBloc TCC (71% and 61% at 90 and 180 days, respectively) compared with the Palindrome Ruby TCC (94% at 90 and 180 days, P < .0001). Multivariate analysis identified only the BioBloc TCC and common femoral access site as independent predictors of worse patency. The unadjusted relative risk (95% confidence interval) for TCC dysfunction with the BioBloc compared with the Palindrome Ruby was 6.0 (2.33-15.53, P < .001), and the relative risk adjusted for access site was 3.2 (1.71-11.96, P = .002). The infection-free rates of the two TCC types were similar (P = .36). The reintervention-free rate for infection or malfunction was significantly better with the Palindrome Ruby TCC (76% and 58% at 90 and 180 days, respectively) than with the BioBloc TCC (60% and 45% at 90 and 180 days, respectively; P = .03). CONCLUSIONS The results support the use of the Palindrome Ruby TCC on the basis of the significantly lower thrombosis and reintervention rate; randomized trials are justified to confirm this finding and to evaluate its role in the prevention of TCC infection.

Secondary Patency of Thrombosed Prosthetic Vascular Access Grafts with Aggressive Surveillance, Monitoring and Endovascular Management

BACKGROUND To study the long-term patency of thrombosed prosthetic vascular access grafts treated with percutaneous mechanical thrombectomy (PMT) followed by aggressive surveillance and monitoring and repeated endovascular interventions. STUDY DESIGN Two hundred seven vascular access grafts presented with first-time thrombosis were treated with PMT using the AngioJet device (n=185) or the Arrow-Trerotola percutaneous thrombolytic device (n=22) followed by angioplasty (+/- stenting) of the anatomical lesion responsible for the thrombotic event. Clinical success was considered at least one successful subsequent hemodialysis session. Graft surveillance/monitoring included clinical and hemodialysis parameters to detect a failing or thrombosed graft. RESULTS PMT was technically successful in 202 cases (97.6%) and clinically successful in 193 cases (93.2%). During follow-up, 149 got thrombosed and either abandoned (n=33) or underwent at least once repeat thrombectomy (n=116); finally 100 grafts were abandoned (n=90), ligated (n=5) or removed (n=5). Endovascular management (0.54 procedures per 100 graft-days, thrombectomy, n=307 sessions and angioplasty, n=162 sessions) increased significantly functional assisted-primary patency rates from 29% and 14% at 1 and 2 years to a secondary patency of 62% and 47%, respectively. Secondary patency was worse in loop grafts (P=.02) and intermediate graft thrombosis (occurred between 31-182 days after graft placement, P<.001) and better when renal failure was due to hypertension or diabetes (compared to other or cryptogenic causes, P=.048) or isolated angioplasty for graft dysfunction during follow-up had been performed (P<.001). Multivariate analysis identified intermediate graft thrombosis and isolated angioplasty as independent predictors of secondary patency (P<.001, relative risk 2.77 and P<.001, relative risk 0.28, respectively). CONCLUSIONS PMT is a highly successful procedure with acceptable long-term secondary patency results, provided that aggressive endovascular management of subsequent thrombotic or dysfunction episode is performed. Further research to identify the causes of intermediate graft thrombosis is justified.

Percutaneous Rheolytic Thrombectomy for Thrombosed Autogenous Fistulae and Prosthetic Arteriovenous Grafts: Outcome after Aggressive Surveillance and Endovascular Management

Purpose: To study the outcome of rheolytic thrombectomy for hemodialysis access occlusion. Methods: A prospective study was conducted of 187 patients (88 men; median age 63 years, range 21–89) with end-stage renal disease treated with the AngioJet rheolytic thrombectomy catheter followed by angioplasty (± stenting) of the culprit lesions in 285 episodes of at least one successful subsequent hemodialysis session. Graft monitoring and surveillance including clinical and hemodialysis parameters, respectively, to detect a failing/failed access. Result: Rheolytic thrombectomy had a technical (immiediate) success rate of 98.2% and a clinical success rate of 95.1%. Technical and clinical success for patients presenting within 2 days of the thrombosis was 99.6%, and 96.6%, respectively, compared to 91.8% (p=0.003, odds ratio 20.8) and 87.8% (p=0.019, odds ratio 4) for later presentation. The number of (4, 3–4) compared to fistulea (2,2–3; p<0.001) and in accesses that had been treated for dysfunction or thrombosis in the past (4, 3–4) compared to accesses that had not (3, 3–4; p=0.07). During follow-up, 95 (36.6%) accesses had no further thrombotic events, 23 (9%) accesses became dysfunction and were treated with endovascular techniques, 137 (52.3%) developed recurren thrombosis for removed for infection. Functional assisted primary patency at 1, 6, 12, and 18 months was 72.4%, 45.1%, 30.3%, and 22.4%, respectively. Reintervention and venous outflow stenosis were associated with better and worse outcomes, respectively; multivariate analysis identified patient age, central vein stenosis, and stenting as additional independent predictors of improved patency. Conclusion: Rheolytic thrombectomy is a highly successful procedure, with acceptable long-term assisted primary patency. Early referral for thrombectomy should be encouraged.

Frequency, risk factors, and management of perigraft seroma after open abdominal aortic aneurysm repair

OBJECTIVE Perigraft seroma (PGS) causing enlargement of the native aneurysm sac after open abdominal aortoiliac aneurysm (AAA) repair is a rarely recognized complication with unknown clinical consequences. This study was undertaken to determine the frequency of PGS, identify associated risk factors, and review resulting complications and their management strategies. METHODS Charts of all patients who underwent open AAA repair at our institution from 1995 to 2009 and had at least one postoperative abdominal cross-sectional imaging study (the study subjects) were retrospectively reviewed. PGS was defined as a perigraft fluid collection present > 3 months postoperatively, ≥ 3-cm in diameter and having a radiodensity ≤ 25 Hounsfield units on computed tomography (CT). Patient records were reviewed for demographics, comorbidities, operative and postoperative variables, and long-term outcome. RESULTS Of the 111 study subjects identified, 13 had aortic reconstruction with Dacron grafts and 98 with polytetrafluoroethylene (PTFE) grafts. Twenty patients (18%) had PGS, all of whom had PTFE grafts (20 of 98; 20.4%). Mean age was 68.5 years and mean aneurysm diameter preoperatively was 6.4 cm (range, 4.0-10.9 cm). The average time from AAA repair to PGS detection was 51 months (range, 4-156 months). PGS averaged 6.0-cm in diameter (range, 3.0-11.0 cm). Multivariate analysis revealed that the following factors were associated with PGS development: diabetes (odds ratio [OR], 3.5; 95% confidence interval [CI], 1.1-21.2; P = .013), smoking (OR, 5.6; 95% CI, 0.73-33.74; P = .01), anticoagulation (OR, 7.2; 95% CI, 2.6-63.3; P = .003), bifurcated graft reconstruction (OR, 8.0; 95% CI, 2.6-94.1; P = .017), and left flank retroperitoneal approach for repair (OR, 7.1; 95% CI, 1.9-26.5; P = .003). Four patients (4 of 20; 20%) required intervention for PGS-related complications: 3 patients for symptomatic PGS expansion (1 patient with rupture) and 1 patient for acute limb ischemia secondary to graft limb compression and thrombosis. Two patients had open exploration, sac evacuation/reduction, and graft replacement with a Dacron graft: 1 patient for a ruptured aneurysm sac and 1 patient for persistent pain associated with sac enlargement. A third patient underwent a failed CT-guided drainage for abdominal pain and was subsequently treated with partial graft excision. The patient with acute limb ischemia was treated with catheter-directed thrombolysis and graft limb stenting. CONCLUSION PGS after open AAA repair occurs more frequently than previously reported. Complications requiring intervention can occur in up to 20% of patients with PGS. A variety of treatment modalities can be used to deal with the complications. Earlier CT surveillance is advised after open AAA repair with a PTFE graft if symptoms are suggestive of PGS development.

Long-term complication and patency rates of Vectra and IMPRA Carboflo Vascular Access Grafts with aggressive monitoring, surveillance and endovascular management

The purpose of this study is to compare infection, pseudoaneurysm formation and patency rates during long-term follow-up of polyurethane and polytetrafluoroethylene (PTFE) vascular access grafts maintained with contemporary endovascular methods. During a 34-month period, 239 polyurethane and 125 carbon-impregnated PTFE vascular access grafts were placed in 324 consecutive patients. Thirty-six patients (9.9%) developed a pseudoaneurysm (anastomotic, n = 6 or at the needle-stick site, n = 30). An additional 19 patients (5.2%) required graft excision for infection. Three-year graft infection and pseudoaneurysm formation (at needle-stick site) rates were similar in polyurethane and PTFE grafts (11% versus 8%, P = 0.61, and 17% versus 23%, P = 0.72, respectively). Three-year secondary patency was better in polyurethane than PTFE grafts (69% versus 57%, respectively, P = 0.012). Straight upper arm polyurethane grafts had the best secondary patency (P = 0.001). Contemporary long-term secondary patency of vascular access grafts is satisfactory. Further follow-up is necessary to compare late infection and pseudoaneurysm formation rates.

The spectrum of radiation enteritis: surgical considerations

Radiation therapy, often used to treat gynecologic and urologic pelvic malignancies, has varying, adverse effects on the bowel. Radiation enteritis may occur from one month to 20 years after irradiation, and disabling symptoms may require surgery in 10 to 20 per cent of patients. From our experience with 20 patients who required surgery for radiation enteritis and who were followed for up to 20 years, we were able to identify three clinical groups. Patients in the first group need only medical treatment for their symptoms and observation, whereas patients in the second group may present with acute, debilitating, life-threatening symptoms that may require emergency surgery. Patients in the third group have a long-standing history of intermittent bowel obstruction and/or enteric fistulas that are best treated with adequate nutritional support followed by timely surgical intervention.

Routine Preoperative Venous and Arterial Mapping Increases Both, Construction and Maturation Rate of Upper Arm Autogenous Arteriovenous Fistulae

Objective: To test the hypothesis that routine preoperative mapping and transposed brachial-basilic vein fistula (TBBVF) increases arteriovenous fistulae (AVFs) construction rates, without altering maturation rate. Patients: Over a 4-year period, 709 vascular accesses were performed, including 467 AVFs (radial-cephalic fistula [RCF], n = 217, brachial-cephalic fistula [BCF], n = 139, TBBVF, n = 111) and 251 prosthetic grafts. During the last 2 years, preoperative mapping was performed routinely by means of ultrasound, and TBBVFs were preferentially used over arteriovenous grafts (AVGs). Results: Over the study, construction rate of upper arm AVF increased significantly from 12% to 53% and use of prosthetic grafts decreased from 55% to 19% (P < .001). Maturation rate of RCFs, BCFs, and TBBVFs during the first part of the study was 75%, 50%, and 30% (P = .003), compared to 79%, 82%, and 86% (P = .43), respectively, during the second part. Conclusions: Routine preoperative upper extremity mapping with ultrasound increases not only AVF construction rate, but also their maturation likelihood.

Patterns and Outcomes of Aortofemoral Bypass Grafting in the Era of Endovascular Interventions

OBJECTIVES The aim of the study is to study contemporary presentation patterns and clinical results in patients undergoing aortofemoral bypass (AFB) surgery. DESIGN This was a retrospective comparative study. MATERIAL AND METHODS During a 14-year period, 269 consecutive patients (mean age 65 years) underwent AFB. Indications included occlusive disease with severe intermittent claudication (IC) (n = 86), critical limb ischaemia (CLI, n = 97) and aneurysmo-occlusive disease (n = 86). RESULTS From 2000-07 on, AFB was performed more frequently for occlusive disease with CLI than for other indications (48% vs. 31% before 2000, P = 0.009) and also in women (51% vs. 32% before 2000, P = 0.003), compared to the period before 2000. Thirty-day mortality was reduced during 2000-2007 to 2.4%, compared with 4.3% during 1993-1999, although this difference was not statistically significant (P = 0.73). Morbidity did not change substantially over the study period. Predictors of 30-day mortality included indication (CLI = 4.1% vs. claudication = 1.2% (P = 0.37)) and chronic kidney disease (CKD, serum creatinine > 1.5 mg dl⁻¹) (11.1% vs. 2.9% in normal renal function, P = 0.07), the latter being the single predictor on multivariate analysis (hazard risk 4.2, P = 0.047). Overall 5 and 10-year assisted primary and secondary patency was 95% and 88%, and 99% and 95%, respectively. Survival at 5 and 10 years was 69% and 48%, respectively. Patient age (hazard risk 1.05, P < 0.001), CKD (hazard risk 1.79, P = 0.018) and diabetes (hazard risk 1.56, P = 0.022) were independent predictors of worse long-term survival. Long-term outcome did not change over the course of the study. CONCLUSIONS In the contemporary era, AFB is more likely to be performed for CLI and in women than in the past. Despite these changes, perioperative mortality and morbidity remain low and long-term outcome excellent.